基蛋生物收盘上涨1.12%，滚动市盈率20.37倍，总市值41.13亿元

Group 1 - The core viewpoint of the articles highlights the current financial performance and market position of Jidan Bio, particularly its low PE ratio compared to the industry average [1][2] - As of May 13, Jidan Bio's closing price was 8.11 yuan, with a PE ratio of 20.37, marking a new low in 25 days, and a total market capitalization of 4.113 billion yuan [1] - The average PE ratio for the medical device industry is 50.06, with a median of 36.80, positioning Jidan Bio at 48th place within the industry [1][2] Group 2 - Jidan Bio specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field in China [1] - The latest quarterly report for Q1 2025 shows Jidan Bio achieved revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1] - As of March 31, 2025, Jidan Bio had 26,747 shareholders, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]